Table 1.
Patient and Transplant Characteristics
| Patient Characteristics | Allogeneic | Autologous | p-value |
|---|---|---|---|
| Number of Patients | 232 (%) | 62 (%) | |
| Age at Transplant | <0.001 | ||
| <20 years | 70 (30) | 9 (15) | |
| 20-40 years | 93 (40) | 19 (31) | |
| >40 years | 69 (30) | 34 (55) | |
| Year of HCT | <0.001 | ||
| 1995-2000 | 145 (63) | 25 (40) | |
| 2001-2006 | 87 (38) | 37 (60) | |
| Sex | 0.18 | ||
| Male | 116 (50) | 37 (60) | |
| Female | 116 (50) | 25 (40) | |
| KPS | 0.91 | ||
| >90% | 178 (77) | 46 (74) | |
| <90% | 48(21) | 14 (23) | |
| Missing | 6 (3) | 2 (3) | |
| Time from CR1 to Relapse (median) | 14 (<1-87) | 17 (<1-85) | 0.08 |
| <12 months | 83 (36) | 18 (29) | |
| >12 Months | 130 (56) | 33 (53) | |
| Missing | 19 (8) | 11 (18) | |
| Time from CR2 to HCT (median) | 2 (<1-45) | 2 (<1-10) | 0.19 |
| <6 months | 202 (87) | 59 (95) | |
| >6 months | 28 (12) | 3 (5) | |
| Missing | 2 (<1) | -- | |
| Conditioning Regimen | |||
| Myeloablative | 213 (92) | 55 (89) | |
| RIC | 15 (7) | 5 (8) | |
| Missing | 4 (2) | 2 (4) | |
| TBI containing | 116 (50) | 47 (76) | 0.001 |
| Non-TBI | 114 (49) | 15 (24) | |
| Donor Type | N/A | ||
| HLA identical Sibling | 124 (53) | ||
| URD well/partially matched | 63 (27) | ||
| Other related | 45 (19) | ||
| Stem cell source | <0.001 | ||
| Marrow | 154 (66) | 8 (12) | |
| Peripheral blood | 78 (34) | 54 (88) | |
| GVHD prophylaxis CSA/Tac±MMF | 203 (88) | N/A | |
| T cell depletion+post-HCT immunosuppression | 24 (10) | ||
| Other | 5 (2) |
†KPS - Karnofsky performance score prior to conditioning, RIC - reduced intensity transplant, TBI- Total Body Irradiation, HLA - human leukocyte antigen, URD - unrelated donor, GVHD - graft vs host disease, CSA - cyclosporine, Tac - tacrolimus, MMF – mycophenolate mofetil.